• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dominari Holdings And 2 Other Stocks Under $3 Insiders Are Buying

    4/11/24 8:41:03 AM ET
    $BRTX
    $DOMH
    Managed Health Care
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BRTX alert in real time by email

    The Dow Jones index closed lower by over 400 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

    Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

    Dominari Holdings

    • The Trade: Dominari Holdings Inc (NASDAQ:DOMH) President Kyle Michael Wool acquired a total of 8,500 shares an average price of $2.99. To acquire these shares, it cost around $25,390.
    • What’s Happening: On April 1, Dominari Holdings posted a narrower quarterly loss.
    • What Dominari Holdings Does: Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development.

    BioRestorative Therapies

    • The Trade: BioRestorative Therapies Inc (NASDAQ:BRTX) Director, VP of Research and Development Francisco Silva acquired a total of 8,308 shares at at an average price of $1.23. To acquire these shares, it cost around $10,229.
    • What’s Happening: On April 8, BioRestorative Therapies partnered with Galen Patient Recruitment to accelerate completion of enrollment in Phase 2 trial of BRTX-100 in chronic lumbar disc disease.
    • What BioRestorative Therapies Does: BioRestorative Therapies Inc is a biotechnology company based in the United States.

    Check This Out: Jim Cramer Says WESCO International Is A Buy, Recommends Buying This Stock Under $20

    Lion Copper and Gold

    • The Trade: Lion Copper and Gold Corp (OTC:LCGMF) Director Tony L Alford acquired a total of 5,072,683 shares at an average price of $0.06. The insider spent around $309,296 to buy those shares.
    • What’s Happening: The company’s stock gained around 6% over the past month.
    • What Lion Copper and Gold Does: Lion Copper and Gold Corp is a Canadian mineral exploration company that is engaged in the acquisition, exploration, and development of copper projects in Nevada, Alaska, and Montana in the United States and British Columbia, Canada.


    Don’t forget to check out our premarket coverage here

    Get the next $BRTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BRTX
    $DOMH

    CompanyDatePrice TargetRatingAnalyst
    BioRestorative Therapies Inc.
    $BRTX
    12/1/2021$37.00Buy
    Roth Capital
    More analyst ratings

    $BRTX
    $DOMH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    COO Devall Christopher Franklin was granted 10,000 shares, increasing direct ownership by 7% to 155,702 units (SEC Form 4)

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    12/12/25 9:48:09 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: CEO Hayes Anthony bought $89,054 worth of shares (23,000 units at $3.87), increasing direct ownership by 1% to 1,750,873 units (SEC Form 4)

    4/A - Dominari Holdings Inc. (0000012239) (Issuer)

    12/10/25 9:22:01 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: President Wool Kyle Michael bought $96,798 worth of shares (25,000 units at $3.87), increasing direct ownership by 2% to 1,211,828 units (SEC Form 4)

    4/A - Dominari Holdings Inc. (0000012239) (Issuer)

    12/10/25 9:20:35 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BRTX
    $DOMH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease

    New blinded data from ~45 patients to date in key pain and function scales and safety and tolerability of the Company's proprietary hypoxic-cultured mesenchymal stem cells to be unveiled on March 28th at the 2026 Orthopaedic Research Society Annual Meeting MELVILLE, N.Y., March 19, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced that new blinded data on approximately 45 patients from its Phase 2 clinical trial evaluating hypoxic-cultured mesenchymal stem cells for the treatment of chronic lumbar disc dise

    3/19/26 8:00:00 AM ET
    $BRTX
    Managed Health Care
    Health Care

    Dominari Releases Letter to Shareholders and Clients

    NEW YORK, March 16, 2026 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) today released the following letter to clients and shareholders: Dear Dominari Clients and Shareholders,As reported in certain media outlets, Dominari Securities LLC ("Dominari" or the "Company") recently received a letter dated March 8, 2026 from the U.S. House Select Committee on the Strategic Competition Between the United States and the Chinese Communist Party requesting information regarding the underwriting of initial public offerings (IPOs) by Chinese companies. Dominari takes this inquiry serio

    3/16/26 8:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New American Drone and Defense Company to be Created Through Merger of Powerus and Aureus Greenway Holdings

    -  Notable Investors of Combined Company Include American Venture Partners Eric Trump and Donald Trump Jr.; Additional Support from Leading U.S. Drone Manufacturer Unusual Machines ("UMAC") and a Strategic $50 Million Investment -  Combination Advances American Domination of Drone Industry and Autonomous Systems Innovation WEST PALM BEACH, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- Aureus Greenway Holdings Inc. (NASDAQ:AGH) today announced that AGH and Autonomous Power Corporation, doing business as Powerus (www.Power.us), a company co-founded by former U.S. Army Special Operations veterans that builds and scales autonomous drone systems for military and commercial use in high-risk environ

    3/9/26 8:00:00 AM ET
    $AGH
    $DOMH
    $UMAC
    Hotels/Resorts
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BRTX
    $DOMH
    SEC Filings

    View All

    SEC Form S-8 filed by Dominari Holdings Inc.

    S-8 - Dominari Holdings Inc. (0000012239) (Filer)

    3/13/26 5:24:42 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Dominari Holdings Inc. (0000012239) (Filer)

    3/5/26 4:30:24 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioRestorative Therapies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)

    2/13/26 8:40:45 PM ET
    $BRTX
    Managed Health Care
    Health Care

    $BRTX
    $DOMH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on BioRestorative Therapies with a new price target

    Roth Capital initiated coverage of BioRestorative Therapies with a rating of Buy and set a new price target of $37.00

    12/1/21 10:21:36 AM ET
    $BRTX
    Managed Health Care
    Health Care

    $BRTX
    $DOMH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: CEO Hayes Anthony bought $89,054 worth of shares (23,000 units at $3.87), increasing direct ownership by 1% to 1,750,873 units (SEC Form 4)

    4/A - Dominari Holdings Inc. (0000012239) (Issuer)

    12/10/25 9:22:01 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: President Wool Kyle Michael bought $96,798 worth of shares (25,000 units at $3.87), increasing direct ownership by 2% to 1,211,828 units (SEC Form 4)

    4/A - Dominari Holdings Inc. (0000012239) (Issuer)

    12/10/25 9:20:35 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President Wool Kyle Michael decreased direct ownership by 1% to 2,453,817 units (SEC Form 4)

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    12/10/25 7:54:17 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BRTX
    $DOMH
    Leadership Updates

    Live Leadership Updates

    View All

    Dominari Expands Strategic Leadership with Appointment of Ambassador Jamie McCourt to Advisory Board

    Dominari Withdraws $2 Billion Shelf Registration NEW YORK, Dec. 8, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) today announced a major enhancement to its strategic leadership with the appointment of Ambassador Jamie McCourt to the Advisory Board of Dominari Securities. Separately, the company has formally withdrawn its previously filed $2 billion shelf registration statement, reflecting confidence in its financial position and growth outlook. Globally recognized diplomat, executive and entrepreneur Ambassador Jamie McCourt Joins Advisory Board Ambassador McCourt

    12/8/25 8:30:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio

    MELVILLE, N.Y., Oct. 22, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced that Crystal Romano has joined its management team. In her role, Ms. Romano will be responsible for leading BioRestorative's global commercial operations and innovation. A seasoned executive with over 19 years of progressive leadership in the medical, aesthetics, and regenerative industries, Ms. Romano is recognized for her expertise in product development and innovation, commercialization, sales and account management, clinical and product training, a

    10/22/25 9:35:00 AM ET
    $BRTX
    Managed Health Care
    Health Care

    Dominari Securities Receives Approval as a Limited Underwriting Member of the New York Stock Exchange

    Enables direct participation in underwriting activities conducted through NYSE and NYSEAmerican platforms NEW YORK, Oct. 9, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") today announced that its wholly owned subsidiary, Dominari Securities LLC, has been approved as a Limited Underwriting member of the New York Stock Exchange and NYSE American Equities (the "Exchanges") effective October 8, 2025. This approval marks an important regulatory milestone for Dominari Securities as it continues to expand its capabilities within U.S. capital m

    10/9/25 8:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BRTX
    $DOMH
    Financials

    Live finance-specific insights

    View All

    Dominari Holdings Issues Letter to Shareholders

    NEW YORK, Jan. 28, 2026 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") today issued the following letter to shareholders: I am pleased to report that 2025 was a transformative and highly successful year for Dominari. Through disciplined execution, expanded distribution capabilities, and a focus on high-growth opportunities across both public and private markets, we delivered strong financial performance and created substantive shareholder value. Shareholder Value Creation As we began 2025, the Company's stock price was just over $1.00. When

    1/28/26 8:30:00 AM ET
    $DOMH
    $TZUP
    $UMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    EDP Services
    Technology

    Dominari Holdings Announces Change of Record Date and Payment Date for $10 Million Cash Dividend

    NEW YORK, Dec. 12, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) is pleased to announce that, following its press release issued on December 11, 2025, the board of directors has updated the record date and payment date for the previously announced special cash dividend of approximately $10 million, or approximately $0.44 per share. The dividend is now payable on or about January 26, 2026, to DOMH's common stock shareholders and certain DOMH warrant holders (on an as-exercised basis) of record as of the close of business on January 5, 2026. For additional informatio

    12/12/25 5:45:00 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Holdings Announces $10 Million Cash Dividend

    NEW YORK, Dec. 11, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) is pleased to announce that its board of directors has authorized a special cash dividend of, in the aggregate, approximately $10 million, or approximately $0.44 per share.  The dividend is payable on or about January 23, 2026, to DOMH's common stock shareholders and certain DOMH warrant holders (on an as-exercised basis) of record as of the close of business on December 31, 2025. For additional information about Dominari Holdings Inc., please visit: https://www.dominariholdings.com/ About Dominari Ho

    12/11/25 7:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BRTX
    $DOMH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Dominari Holdings Inc.

    SC 13D/A - Dominari Holdings Inc. (0000012239) (Subject)

    6/13/24 8:56:04 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Dominari Holdings Inc.

    SC 13D/A - Dominari Holdings Inc. (0000012239) (Subject)

    6/13/24 4:32:07 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by BioRestorative Therapies Inc. (Amendment)

    SC 13D/A - BioRestorative Therapies, Inc. (0001505497) (Subject)

    3/6/24 4:34:22 PM ET
    $BRTX
    Managed Health Care
    Health Care